444 related articles for article (PubMed ID: 26365960)
1. Therapeutic Effects of Sodium Hyaluronate on Ocular Surface Damage Induced by Benzalkonium Chloride Preserved Anti-glaucoma Medications.
Liu X; Yu FF; Zhong YM; Guo XX; Mao Z
Chin Med J (Engl); 2015 Sep; 128(18):2444-9. PubMed ID: 26365960
[TBL] [Abstract][Full Text] [Related]
2. Sodium hyaluronate decreases ocular surface toxicity induced by benzalkonium chloride-preserved latanoprost: an in vivo study.
Yu F; Liu X; Zhong Y; Guo X; Li M; Mao Z; Xiao H; Yang S
Invest Ophthalmol Vis Sci; 2013 May; 54(5):3385-93. PubMed ID: 23620425
[TBL] [Abstract][Full Text] [Related]
3. [Protection effect of sodium hyaluronate on ocular surface toxicity induced by Benzalkonium chloride-preserved brimonidine in rabbits].
Yu FF; Liu X; Zhong YM; Mao Z; Guo XX; Li M; Cao D; Chen XX
Zhonghua Yan Ke Za Zhi; 2013 Nov; 49(11):973-80. PubMed ID: 24512997
[TBL] [Abstract][Full Text] [Related]
4. [Therapeutic effects of Pyranoprofen on the mouse dry eye induced by topical medication of Benzalkonium Chloride].
He H; Liu ZG; Lin ZR; Liu XC; He H; Xiao QG
Zhonghua Yan Ke Za Zhi; 2012 Jan; 48(1):33-40. PubMed ID: 22490914
[TBL] [Abstract][Full Text] [Related]
5. Additive Effect of preservative-free sodium hyaluronate 0.1% in treatment of dry eye syndrome with diquafosol 3% eye drops.
Hwang HS; Sung YM; Lee WS; Kim EC
Cornea; 2014 Sep; 33(9):935-41. PubMed ID: 25055152
[TBL] [Abstract][Full Text] [Related]
6. A rabbit dry eye model induced by topical medication of a preservative benzalkonium chloride.
Xiong C; Chen D; Liu J; Liu B; Li N; Zhou Y; Liang X; Ma P; Ye C; Ge J; Wang Z
Invest Ophthalmol Vis Sci; 2008 May; 49(5):1850-6. PubMed ID: 18436819
[TBL] [Abstract][Full Text] [Related]
7. Effects of polyquaternium- and benzalkonium-chloride-preserved travoprost on ocular surfaces: an impression cytology study.
Sezgin Akçay Bİ; Güney E; Bozkurt TK; Topal CS; Akkan JC; Ünlü C
J Ocul Pharmacol Ther; 2014 Sep; 30(7):548-53. PubMed ID: 24901262
[TBL] [Abstract][Full Text] [Related]
8. [Corneal sensitivity in patients treated medically for glaucoma or ocular hypertension].
Van Went C; Alalwani H; Brasnu E; Pham J; Hamard P; Baudouin C; Labbé A
J Fr Ophtalmol; 2011 Dec; 34(10):684-90. PubMed ID: 22093372
[TBL] [Abstract][Full Text] [Related]
9. Symptoms and signs of tear film dysfunction in glaucomatous patients.
Valente C; Iester M; Corsi E; Rolando M
J Ocul Pharmacol Ther; 2011 Jun; 27(3):281-5. PubMed ID: 21557633
[TBL] [Abstract][Full Text] [Related]
10. Influence of timolol, benzalkonium-preserved timolol, and benzalkonium-preserved brimonidine on oxidative stress biomarkers in the tear film.
Sedlak L; Wojnar W; Zych M; Wyględowska-Promieńska D
Cutan Ocul Toxicol; 2020 Sep; 39(3):260-268. PubMed ID: 32594785
[TBL] [Abstract][Full Text] [Related]
11. Ocular Surface Disease in Glaucoma: Effect of Polypharmacy and Preservatives.
Ramli N; Supramaniam G; Samsudin A; Juana A; Zahari M; Choo MM
Optom Vis Sci; 2015 Sep; 92(9):e222-6. PubMed ID: 25730335
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of ocular surface disease in glaucoma patients.
Leung EW; Medeiros FA; Weinreb RN
J Glaucoma; 2008 Aug; 17(5):350-5. PubMed ID: 18703943
[TBL] [Abstract][Full Text] [Related]
13. Relationship between OSDI score and biomicroscopic ocular surface damages in glaucomatous patients treated with preserved antiglaucomatous eye drops.
Lajmi H; Chelly Z; Choura R; Mansour KB; Hmaied W
J Fr Ophtalmol; 2021 Nov; 44(9):1326-1331. PubMed ID: 34325926
[TBL] [Abstract][Full Text] [Related]
14. Effect of 0.3% Hydroxypropyl Methylcellulose/Dextran Versus 0.18% Sodium Hyaluronate in the Treatment of Ocular Surface Disease in Glaucoma Patients: A Randomized, Double-Blind, and Controlled Study.
Prabhasawat P; Ruangvaravate N; Tesavibul N; Thewthong M
J Ocul Pharmacol Ther; 2015; 31(6):323-9. PubMed ID: 26090941
[TBL] [Abstract][Full Text] [Related]
15. Tear film osmolarity in patients treated for glaucoma or ocular hypertension.
Labbé A; Terry O; Brasnu E; Van Went C; Baudouin C
Cornea; 2012 Sep; 31(9):994-9. PubMed ID: 22710490
[TBL] [Abstract][Full Text] [Related]
16. Assessment of ocular surface disease in glaucoma patients with benzalkonium chloride-preserved latanoprost eye drops: a short-term longitudinal study.
Su CC; Lee YC; Lee PRC
Graefes Arch Clin Exp Ophthalmol; 2021 May; 259(5):1243-1251. PubMed ID: 33433642
[TBL] [Abstract][Full Text] [Related]
17. Clinical audit examining the impact of benzalkonium chloride-free anti-glaucoma medications on patients with symptoms of ocular surface disease.
Goldberg I; Graham SL; Crowston JG; d'Mellow G;
Clin Exp Ophthalmol; 2015 Apr; 43(3):214-20. PubMed ID: 25196488
[TBL] [Abstract][Full Text] [Related]
18. Long term treatment with sodium hyaluronate-containing artificial tears reduces ocular surface damage in patients with dry eye.
Aragona P; Papa V; Micali A; Santocono M; Milazzo G
Br J Ophthalmol; 2002 Feb; 86(2):181-4. PubMed ID: 11815344
[TBL] [Abstract][Full Text] [Related]
19. [Effects of artificial tears on ocular surface in glaucomatous patients with long-term instillation of preserved antiglaucoma eye drops].
Makashova NV; Vasilieva AE; Kolosova OY
Vestn Oftalmol; 2018; 134(2):59-65. PubMed ID: 29771886
[TBL] [Abstract][Full Text] [Related]
20. A Randomized Multicenter Study Comparing 0.1%, 0.15%, and 0.3% Sodium Hyaluronate with 0.05% Cyclosporine in the Treatment of Dry Eye.
Park Y; Song JS; Choi CY; Yoon KC; Lee HK; Kim HS
J Ocul Pharmacol Ther; 2017 Mar; 33(2):66-72. PubMed ID: 27929721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
